BIRC5 and prostate carcinoma: Additionally, a study of an HLA-DR restricted survivin-derived CD4+ T cell epitope in a multi-peptide cocktail immunotherapy trial for prostate carcinoma patients indicated that the survivin peptides are promiscuously presented by several human HLA-DRB1 molecules, and they are naturally processed through dendritic cells.